MAP3K1 and breast carcinoma: Furthermore, the miR-302 family (miR-302a/b/c/d) has been proven to sensitize breast cancer cells to doxorubicin by suppressing P-gp through the inhibition of MAP/ERK kinase kinase 1 (MEKK1) (Zhao et al., 2016).